Publicacións en colaboración con investigadores/as de Instituto de Neurociencias del Principado de Asturias (22)

2023

  1. One-way or two-way sweet link between theobromine and depression?

    BMC Psychiatry

  2. The adenosine A2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling

    International Review of Neurobiology (Academic Press Inc.), pp. 49-71

  3. The olfactory Olfr-78/51E2 receptor interacts with the adenosine A2A receptor. Effect of menthol and 1,8-cineole on A2A receptor-mediated signaling

    Frontiers in Pharmacology, Vol. 14

2022

  1. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

  2. Plant-derived compounds, vitagens, vitagenes and mitochondrial function

    PharmaNutrition

2021

  1. Antixoxidant supplements versus health benefits of brief/intermittent exposure to potentially toxic physical or chemical agents

    Current Issues in Molecular Biology, Vol. 43, Núm. 2, pp. 650-664

  2. Cuprizone‐induced neurotoxicity in human neural cell lines is mediated by a reversible mitochondrial dysfunction: Relevance for demyelination models

    Brain Sciences, Vol. 11, Núm. 2, pp. 1-16

  3. Neuroprotective effect of apolipoprotein d in cuprizone-induced cell line models: A potential therapeutic approach for multiple sclerosis and demyelinating diseases

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-23

2020

  1. Adenosine a2a and a3 receptors are able to interact with each other. A further piece in the puzzle of adenosine receptor-mediated signaling

    International Journal of Molecular Sciences, Vol. 21, Núm. 14, pp. 1-14

  2. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  3. Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum

    Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42

  4. Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease

    Frontiers in Aging Neuroscience, Vol. 12

  5. Natural Compounds as Guides for the Discovery of Drugs Targeting G-Protein-Coupled Receptors

    Molecules (Basel, Switzerland), Vol. 25, Núm. 21

2019

  1. Antioxidant defense mechanisms in erythrocytes and in the central nervous system

    Antioxidants, Vol. 8, Núm. 2

  2. Antioxidants versus food antioxidant additives and food preservatives

    Antioxidants, Vol. 8, Núm. 11

  3. Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 9-16

  4. Hormetic and mitochondria-related mechanisms of antioxidant action of phytochemicals

    Antioxidants, Vol. 8, Núm. 9

  5. Lessons on differential neuronal-death-vulnerability from familial cases of parkinson’s and alzheimer’s diseases

    International Journal of Molecular Sciences, Vol. 20, Núm. 13

  6. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

  7. Why have transgenic rodent models failed to successfully mimic Alzheimer’s disease. How can we develop effective drugs without them?

    Expert Opinion on Drug Discovery